CN119213503A - 用于在禁食时段期间递送胰岛素的胰岛素管理 - Google Patents
用于在禁食时段期间递送胰岛素的胰岛素管理 Download PDFInfo
- Publication number
- CN119213503A CN119213503A CN202380041218.9A CN202380041218A CN119213503A CN 119213503 A CN119213503 A CN 119213503A CN 202380041218 A CN202380041218 A CN 202380041218A CN 119213503 A CN119213503 A CN 119213503A
- Authority
- CN
- China
- Prior art keywords
- insulin
- delivery device
- user
- blood glucose
- delivery
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 title claims abstract description 1670
- 102000004877 Insulin Human genes 0.000 title claims abstract description 835
- 108090001061 Insulin Proteins 0.000 title claims abstract description 835
- 229940125396 insulin Drugs 0.000 title claims abstract description 835
- 238000012384 transportation and delivery Methods 0.000 claims abstract description 717
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims abstract description 466
- 239000008103 glucose Substances 0.000 claims abstract description 466
- 239000008280 blood Substances 0.000 claims abstract description 437
- 210000004369 blood Anatomy 0.000 claims abstract description 437
- 238000000034 method Methods 0.000 claims abstract description 201
- 238000005259 measurement Methods 0.000 claims abstract description 188
- 238000012937 correction Methods 0.000 claims abstract description 129
- 230000000694 effects Effects 0.000 claims abstract description 93
- 238000007726 management method Methods 0.000 claims abstract description 85
- 230000000977 initiatory effect Effects 0.000 claims abstract description 55
- 230000004044 response Effects 0.000 claims abstract description 29
- 238000002360 preparation method Methods 0.000 claims abstract description 13
- 235000020925 non fasting Nutrition 0.000 claims description 104
- 235000012054 meals Nutrition 0.000 claims description 72
- 238000002560 therapeutic procedure Methods 0.000 claims description 50
- 230000006870 function Effects 0.000 claims description 42
- 229940127560 insulin pen Drugs 0.000 claims description 40
- 206010022489 Insulin Resistance Diseases 0.000 claims description 26
- 230000004913 activation Effects 0.000 claims description 26
- 230000037452 priming Effects 0.000 claims description 22
- 238000002347 injection Methods 0.000 claims description 16
- 239000007924 injection Substances 0.000 claims description 16
- 238000001514 detection method Methods 0.000 claims description 13
- 238000002716 delivery method Methods 0.000 claims description 6
- 238000012549 training Methods 0.000 claims description 6
- 230000001755 vocal effect Effects 0.000 claims description 5
- 238000004364 calculation method Methods 0.000 description 50
- 238000011282 treatment Methods 0.000 description 50
- 238000004422 calculation algorithm Methods 0.000 description 40
- 231100000817 safety factor Toxicity 0.000 description 31
- 238000004891 communication Methods 0.000 description 26
- 230000008569 process Effects 0.000 description 25
- 238000005096 rolling process Methods 0.000 description 25
- 230000009471 action Effects 0.000 description 21
- 206010012601 diabetes mellitus Diseases 0.000 description 21
- 238000001914 filtration Methods 0.000 description 20
- 230000007423 decrease Effects 0.000 description 19
- 230000002218 hypoglycaemic effect Effects 0.000 description 19
- 230000008859 change Effects 0.000 description 17
- 230000003247 decreasing effect Effects 0.000 description 17
- 238000010586 diagram Methods 0.000 description 16
- 230000007958 sleep Effects 0.000 description 16
- 208000013016 Hypoglycemia Diseases 0.000 description 15
- 150000001720 carbohydrates Chemical class 0.000 description 11
- 235000014633 carbohydrates Nutrition 0.000 description 11
- 238000004590 computer program Methods 0.000 description 11
- 230000002618 waking effect Effects 0.000 description 11
- 230000000670 limiting effect Effects 0.000 description 10
- 230000007774 longterm Effects 0.000 description 10
- 238000003860 storage Methods 0.000 description 10
- 230000000153 supplemental effect Effects 0.000 description 9
- 230000007704 transition Effects 0.000 description 9
- 238000011156 evaluation Methods 0.000 description 8
- 238000012545 processing Methods 0.000 description 8
- 230000001052 transient effect Effects 0.000 description 8
- 102000051325 Glucagon Human genes 0.000 description 7
- 108060003199 Glucagon Proteins 0.000 description 7
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 7
- 229960004666 glucagon Drugs 0.000 description 7
- 238000009499 grossing Methods 0.000 description 7
- 230000037081 physical activity Effects 0.000 description 7
- 238000009825 accumulation Methods 0.000 description 6
- 230000001413 cellular effect Effects 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 230000007246 mechanism Effects 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 230000000630 rising effect Effects 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 230000008901 benefit Effects 0.000 description 5
- 238000012377 drug delivery Methods 0.000 description 5
- 201000001421 hyperglycemia Diseases 0.000 description 5
- 230000000422 nocturnal effect Effects 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 102000016261 Long-Acting Insulin Human genes 0.000 description 4
- 108010092217 Long-Acting Insulin Proteins 0.000 description 4
- 229940100066 Long-acting insulin Drugs 0.000 description 4
- 206010062519 Poor quality sleep Diseases 0.000 description 4
- 230000002641 glycemic effect Effects 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 238000010295 mobile communication Methods 0.000 description 4
- 230000000284 resting effect Effects 0.000 description 4
- 238000007920 subcutaneous administration Methods 0.000 description 4
- 239000000853 adhesive Substances 0.000 description 3
- 230000001070 adhesive effect Effects 0.000 description 3
- 238000004883 computer application Methods 0.000 description 3
- 238000012790 confirmation Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 230000001976 improved effect Effects 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 238000012417 linear regression Methods 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000011277 treatment modality Methods 0.000 description 3
- 238000012935 Averaging Methods 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000003914 insulin secretion Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 230000000737 periodic effect Effects 0.000 description 2
- 238000003825 pressing Methods 0.000 description 2
- 230000004224 protection Effects 0.000 description 2
- 230000004622 sleep time Effects 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 230000001131 transforming effect Effects 0.000 description 2
- -1 0.1 units Chemical group 0.000 description 1
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 1
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 description 1
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 102100040918 Pro-glucagon Human genes 0.000 description 1
- 229940123452 Rapid-acting insulin Drugs 0.000 description 1
- 108010026951 Short-Acting Insulin Proteins 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000013500 data storage Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000001667 episodic effect Effects 0.000 description 1
- 235000013410 fast food Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 1
- 229960003105 metformin Drugs 0.000 description 1
- 230000006855 networking Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 229940125395 oral insulin Drugs 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 230000011218 segmentation Effects 0.000 description 1
- 239000004065 semiconductor Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
- A61M5/168—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body
- A61M5/172—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body electrical or electronic
- A61M5/1723—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body electrical or electronic using feedback of body parameters, e.g. blood-sugar, pressure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
- A61M5/142—Pressure infusion, e.g. using pumps
- A61M5/14244—Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
- G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
- G16H20/17—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered via infusion or injection
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H40/00—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices
- G16H40/60—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices
- G16H40/63—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for local operation
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H40/00—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices
- G16H40/60—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices
- G16H40/67—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for remote operation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
- A61M5/142—Pressure infusion, e.g. using pumps
- A61M2005/14208—Pressure infusion, e.g. using pumps with a programmable infusion control system, characterised by the infusion program
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/04—Liquids
- A61M2202/0468—Liquids non-physiological
- A61M2202/0486—Glucose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/50—General characteristics of the apparatus with microprocessors or computers
- A61M2205/52—General characteristics of the apparatus with microprocessors or computers with memories providing a history of measured variating parameters of apparatus or patient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2230/00—Measuring parameters of the user
- A61M2230/20—Blood composition characteristics
- A61M2230/201—Glucose concentration
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
- G16H20/60—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to nutrition control, e.g. diets
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Primary Health Care (AREA)
- Medical Informatics (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Anesthesiology (AREA)
- Animal Behavior & Ethology (AREA)
- Vascular Medicine (AREA)
- Veterinary Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Business, Economics & Management (AREA)
- General Business, Economics & Management (AREA)
- Diabetes (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
- Medical Treatment And Welfare Office Work (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263332001P | 2022-04-18 | 2022-04-18 | |
| US63/332,001 | 2022-04-18 | ||
| PCT/IB2023/053951 WO2023203478A1 (en) | 2022-04-18 | 2023-04-18 | Insulin management for delivering insulin during a fasting period |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN119213503A true CN119213503A (zh) | 2024-12-27 |
Family
ID=86330844
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202380041218.9A Pending CN119213503A (zh) | 2022-04-18 | 2023-04-18 | 用于在禁食时段期间递送胰岛素的胰岛素管理 |
| CN202380041221.0A Pending CN119213504A (zh) | 2022-04-18 | 2023-04-18 | 用于在禁食时段期间递送胰岛素的胰岛素管理 |
| CN202380041161.2A Pending CN119213502A (zh) | 2022-04-18 | 2023-04-18 | 用于在禁食时段期间递送胰岛素的胰岛素管理 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202380041221.0A Pending CN119213504A (zh) | 2022-04-18 | 2023-04-18 | 用于在禁食时段期间递送胰岛素的胰岛素管理 |
| CN202380041161.2A Pending CN119213502A (zh) | 2022-04-18 | 2023-04-18 | 用于在禁食时段期间递送胰岛素的胰岛素管理 |
Country Status (5)
| Country | Link |
|---|---|
| US (3) | US20230330336A1 (https=) |
| EP (3) | EP4511839A1 (https=) |
| JP (3) | JP2025513420A (https=) |
| CN (3) | CN119213503A (https=) |
| WO (3) | WO2023203479A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20230330336A1 (en) * | 2022-04-18 | 2023-10-19 | Luna Health, Inc. | Systems, devices and related methods of coordinating insulin management and delivery modes in fasting & non-fasting periods |
| US12576208B2 (en) * | 2022-04-26 | 2026-03-17 | Dexcom, Inc. | System and method for titrating basal insulin doses |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004093648A2 (en) * | 2003-04-18 | 2004-11-04 | Insulet Corporation | User interface for infusion pump remote controller and method of using the same |
| US20080172031A1 (en) * | 2006-10-17 | 2008-07-17 | Blomquist Michael L | Insulin pump having correction factors |
| US10350354B2 (en) * | 2007-06-21 | 2019-07-16 | Roche Diagnostics Operations, Inc. | Device and method for preventing hypoglicemia |
| US9333297B2 (en) * | 2008-05-08 | 2016-05-10 | Minipumps, Llc | Drug-delivery pump with intelligent control |
| US8140275B2 (en) * | 2008-07-18 | 2012-03-20 | Insulet Corporation | Calculating insulin on board for extended bolus being delivered by an insulin delivery device |
| US7959598B2 (en) * | 2008-08-20 | 2011-06-14 | Asante Solutions, Inc. | Infusion pump systems and methods |
| US8257300B2 (en) * | 2009-05-22 | 2012-09-04 | Abbott Diabetes Care Inc. | Safety features for integrated insulin delivery system |
| US8843321B2 (en) * | 2010-01-26 | 2014-09-23 | Roche Diagnostics Operations, Inc. | Methods and systems for processing glucose data measured from a person having diabetes |
| US10195343B2 (en) * | 2010-02-05 | 2019-02-05 | Deka Products Limited Partnership | Devices, methods and systems for wireless control of medical devices |
| WO2011112753A1 (en) * | 2010-03-10 | 2011-09-15 | Abbott Diabetes Care Inc. | Systems, devices and methods for managing glucose levels |
| KR101851440B1 (ko) * | 2012-08-22 | 2018-04-23 | 에프. 호프만-라 로슈 아게 | 이송 유체를 이송하기 위한 이송 시스템 및 방법 |
| US10569015B2 (en) * | 2013-12-02 | 2020-02-25 | Bigfoot Biomedical, Inc. | Infusion pump system and method |
| BR112017019269B1 (pt) * | 2015-03-09 | 2022-11-29 | Amgen Inc | Mecanismos de acionamento para uso com um recipiente de drogas e bomba de distribuição de drogas |
| US20170213002A1 (en) * | 2016-01-27 | 2017-07-27 | The Trustees Of Princeton University | Safety-driven architecture for implantable and wearable medical devices |
| US11062798B2 (en) * | 2016-06-07 | 2021-07-13 | Aseko, Inc. | Managing insulin administration |
| JP6940531B2 (ja) * | 2016-06-30 | 2021-09-29 | ノボ・ノルデイスク・エー／エス | インスリン計画アドヒアランスデータの分析のためのシステムおよび方法 |
| JP7064452B2 (ja) * | 2016-06-30 | 2022-05-10 | ノボ・ノルデイスク・エー／エス | インスリン計画アドヒアランスデータの分析のためのシステムおよび方法 |
| MA45601A (fr) * | 2016-07-08 | 2019-05-15 | Novo Nordisk As | Systèmes et procédés de détermination de la sensibilité à l'insuline |
| MA46993A (fr) * | 2016-11-29 | 2019-10-09 | Novo Nordisk As | Trousse de départ pour titrage de taux de base |
| US10881792B2 (en) * | 2017-01-13 | 2021-01-05 | Bigfoot Biomedical, Inc. | System and method for adjusting insulin delivery |
| US11033682B2 (en) * | 2017-01-13 | 2021-06-15 | Bigfoot Biomedical, Inc. | Insulin delivery methods, systems and devices |
| US10583250B2 (en) * | 2017-01-13 | 2020-03-10 | Bigfoot Biomedical, Inc. | System and method for adjusting insulin delivery |
| US11147920B2 (en) * | 2017-04-18 | 2021-10-19 | Lifescan Ip Holdings, Llc | Diabetes management system with automatic basal and manual bolus insulin control |
| GB201710822D0 (en) * | 2017-07-05 | 2017-08-16 | Zealand Pharma As | Methods and medical uses relating to the treatment of hypoglycaemia |
| ES3050085T3 (en) * | 2017-07-07 | 2025-12-19 | Neuroderm Ltd | Device for subcutaneous delivery of fluid medicament |
| EP4685812A3 (en) * | 2018-02-09 | 2026-04-22 | DexCom, Inc. | System for decision support |
| AR114755A1 (es) * | 2018-04-09 | 2020-10-14 | Hoffmann La Roche | Método y dispositivos para la administración de insulina |
| US11158413B2 (en) * | 2018-04-23 | 2021-10-26 | Medtronic Minimed, Inc. | Personalized closed loop medication delivery system that utilizes a digital twin of the patient |
| EP3966560A4 (en) * | 2019-05-10 | 2023-01-25 | Companion Medical, Inc. | TRENDABLE DOSE CALCULATOR WITH CONTINUOUS GLUCOSE MONITORING |
| KR20220066891A (ko) | 2019-09-27 | 2022-05-24 | 이데미쓰 고산 가부시키가이샤 | 냉동기용 윤활유 조성물 |
| US11935637B2 (en) * | 2019-09-27 | 2024-03-19 | Insulet Corporation | Onboarding and total daily insulin adaptivity |
| US12458753B2 (en) * | 2020-01-08 | 2025-11-04 | Dexcom, Inc. | Managing bolus doses |
| US20210259591A1 (en) * | 2020-02-20 | 2021-08-26 | Dexcom, Inc. | Machine learning in an artificial pancreas |
| US12191017B2 (en) * | 2020-03-23 | 2025-01-07 | Medtronic Minimed, Inc. | Systems and methods for medicine administration and tracking |
| US20250319249A1 (en) * | 2020-08-13 | 2025-10-16 | Eoflow Co., Ltd. | Controlling method of drug injection device |
| US11951284B2 (en) * | 2020-08-27 | 2024-04-09 | Tandem Diabetes Care, Inc. | Transitioning to other modes in automated insulin delivery |
| WO2022097057A1 (en) | 2020-11-05 | 2022-05-12 | Luna Health, Inc. | Medication fluid delivery device |
| EP4256571A1 (en) * | 2020-12-01 | 2023-10-11 | Medtronic MiniMed, Inc. | Systems and methods for optimizing medicament dosing |
| EP4268236A1 (en) * | 2020-12-23 | 2023-11-01 | Dexcom, Inc. | Bolus advisor with correction boluses based on risk, carb-free bolus recommender, and meal acknowledgement |
| CN116917996A (zh) * | 2020-12-31 | 2023-10-20 | 英赛罗公司 | 具有图形用户界面的药品输送系统 |
| US11160925B1 (en) * | 2021-01-29 | 2021-11-02 | Insulet Corporation | Automatic drug delivery system for delivery of a GLP-1 therapeutic |
| US20220273873A1 (en) * | 2021-02-26 | 2022-09-01 | Insulet Corporation | Techniques for optimizing usage of an automatic drug delivery system |
| US12521486B2 (en) * | 2021-07-16 | 2026-01-13 | Insulet Corporation | Method for modification of insulin delivery during pregnancy in automatic insulin delivery systems |
| EP4154926A1 (en) * | 2021-09-27 | 2023-03-29 | Ypsomed AG | An improved needle insertion mechanism for an injection or infusion device |
| US20230330336A1 (en) * | 2022-04-18 | 2023-10-19 | Luna Health, Inc. | Systems, devices and related methods of coordinating insulin management and delivery modes in fasting & non-fasting periods |
| US20230343430A1 (en) * | 2022-04-21 | 2023-10-26 | Insulet Corporation | Medicament adaptation and safety monitoring |
| US20240075208A1 (en) * | 2022-09-01 | 2024-03-07 | Insulet Corporation | Method for detecting occlusions in a fluid path using blood glucose readings |
| WO2024081559A1 (en) * | 2022-10-11 | 2024-04-18 | Insulet Corporation | System and method for determining the effect of ingestion of meals of varying carbohydrate content |
| EP4665224A1 (en) * | 2023-02-13 | 2025-12-24 | Insulet Corporation | System and method for reducing cgm warm-up time by application of optical energy |
-
2023
- 2023-04-17 US US18/135,447 patent/US20230330336A1/en active Pending
- 2023-04-17 US US18/135,412 patent/US20230330334A1/en active Pending
- 2023-04-17 US US18/135,417 patent/US20230330335A1/en active Pending
- 2023-04-18 CN CN202380041218.9A patent/CN119213503A/zh active Pending
- 2023-04-18 EP EP23722958.8A patent/EP4511839A1/en active Pending
- 2023-04-18 JP JP2024561999A patent/JP2025513420A/ja active Pending
- 2023-04-18 CN CN202380041221.0A patent/CN119213504A/zh active Pending
- 2023-04-18 JP JP2024561998A patent/JP2025513419A/ja active Pending
- 2023-04-18 EP EP23722959.6A patent/EP4511840A1/en active Pending
- 2023-04-18 JP JP2024561996A patent/JP2025514790A/ja active Pending
- 2023-04-18 CN CN202380041161.2A patent/CN119213502A/zh active Pending
- 2023-04-18 WO PCT/IB2023/053952 patent/WO2023203479A1/en not_active Ceased
- 2023-04-18 EP EP23722960.4A patent/EP4511841A1/en active Pending
- 2023-04-18 WO PCT/IB2023/053950 patent/WO2023203477A1/en not_active Ceased
- 2023-04-18 WO PCT/IB2023/053951 patent/WO2023203478A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| EP4511840A1 (en) | 2025-02-26 |
| WO2023203479A1 (en) | 2023-10-26 |
| US20230330334A1 (en) | 2023-10-19 |
| WO2023203477A1 (en) | 2023-10-26 |
| WO2023203478A1 (en) | 2023-10-26 |
| JP2025513419A (ja) | 2025-04-24 |
| JP2025513420A (ja) | 2025-04-24 |
| US20230330335A1 (en) | 2023-10-19 |
| CN119213502A (zh) | 2024-12-27 |
| CN119213504A (zh) | 2024-12-27 |
| EP4511839A1 (en) | 2025-02-26 |
| EP4511841A1 (en) | 2025-02-26 |
| JP2025514790A (ja) | 2025-05-09 |
| US20230330336A1 (en) | 2023-10-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2022291455B2 (en) | Network Topology For Insulin Pump Systems | |
| US11471598B2 (en) | Operating an infusion pump system | |
| CN108472440B (zh) | 操作多模式药物输送系统 | |
| CN106659843B (zh) | 胰高血糖素施用系统和方法 | |
| AU2018250241A1 (en) | Insulin-on-board accounting in an artificial pancreas system | |
| US11911595B2 (en) | Systems and methods for automated insulin delivery response to meal announcements | |
| CN119213503A (zh) | 用于在禁食时段期间递送胰岛素的胰岛素管理 | |
| US20250325743A1 (en) | Drive coupling and sensing systems, and methods for fluid delivery pumps | |
| US12592306B2 (en) | Devices and methods for initialization of drug delivery devices using measured analyte sensor information | |
| US12115349B2 (en) | Systems and methods for managing diabetes | |
| US20260069776A1 (en) | Systems and methods for managing diabetes | |
| CA3009840C (en) | Network topology for insulin pump systems | |
| HK40062650A (en) | Operating multi-modal medicine delivery systems | |
| HK1237289B (zh) | 胰高血糖素施用系统和方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |